The first results of a study on the use of monthly RNAi with ARO-HBV in patients with chronic hepatitis B virus infections indicate that the treatment effectively reduced all measurable viral products, including HBsAg.
The oral CGRP antagonist becomes the first in its class approved for the indication.
The indication for letermovir represents a significant milestone, since CMV infection remains the most common complication of stem cell transplantation for patients with cancer.